Therakos, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Therakos, Inc. - overview
Established
1984
Location
Staines-upon-Thames, -, UK
Primary Industry
Medical Devices & Equipment
About
Therakos, Inc. is a US-based company specializing in innovative medical technologies, focusing on the treatment of Cutaneous T-Cell Lymphoma through advanced photopheresis systems. Therakos, Inc. develops medical solutions for treating Cutaneous T-Cell Lymphoma (CTCL).
Based in Raritan, US, the company was recently acquired by CVC and investors for USD 925 mn on August 5, 2024, from Mallinckrodt, Inc. Therakos has completed a total of 3 deals. Therakos, LLC specializes in innovative medical solutions for the treatment of Cutaneous T-Cell Lymphoma (CTCL), primarily through its core product, the THERAKOS® CELLEX® Photopheresis System. This system employs extracorporeal photopheresis, involving the selective removal and treatment of leukocyte-enriched blood using ultraviolet-A (UVA) irradiation with the photoactive drug, UVADEX® (methoxsalen).
This technology aims to provide palliative treatment for patients with CTCL resistant to conventional therapies, targeting healthcare providers with expertise in hematology and oncology in the United States. Therakos, LLC generates revenue through the sale of its proprietary medical devices and associated products, particularly the THERAKOS® CELLEX® Photopheresis System and UVADEX® (methoxsalen) Sterile Solution. Transactions typically occur in a B2B format, with healthcare institutions purchasing the systems for use in patient treatments. The revenue model is sustained by partnerships with healthcare providers who utilize the system in clinical settings, ensuring consistent demand for both the device and photopheresis solutions, supported by specialized training for practitioners.
The recent acquisition by CVC and individual investors aims to enhance Therakos, Inc. 's capabilities in the healthcare sector. The strategic focus will include potential product innovations and advancements in treatment methodologies. Specific markets for expansion have not been disclosed, but the acquisition is expected to strengthen Therakos' position within existing regions, ensuring they maintain a robust market presence.
Current Investors
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices
Website
www.therakos.com/
Verticals
Manufacturing
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Therakos, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Corporate Carve Out | Completed | Therakos, Inc. | - | ||||||||
| Trade Sale | Completed | Therakos, Inc. | - | ||||||||
| Buyout | Completed | Therakos, Inc. | - |
Displaying 1 - 3 of 3
Therakos, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.